Foghorn Therapeutics Inc. reports results for the quarter ended in March - Earnings Summary
08/05/2024 13:01
* Foghorn Therapeutics Inc. FHTX.OQ reported a quarterly
adjusted loss of 59 cents per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of -73 cents. The mean expectation of
four analysts for the quarter was for a loss of 63 cents per
share. Wall Street expected results to range from -87 cents
to -51 cents per share.
* Revenue fell 4.9% to $5.05 million from a year ago;
analysts
expected $6.91 million.
* Foghorn Therapeutics Inc.'s reported EPS for the quarter
was a
loss of 59 cents.
* The company reported a quarterly loss of $25.02 million.
* Foghorn Therapeutics Inc. shares had fallen by 16.1% this
quarter and lost 12.7% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 8.4%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Foghorn
Therapeutics Inc. is $14.50
This summary was machine generated from LSEG data May 8 at 12:00
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.63 -0.59 Beat
Dec. 31 2023 -0.76 -0.57 Beat
Sep. 30 2023 -0.75 -0.34 Beat
Jun. 30 2023 -0.73 -0.70 Beat